Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148]
Discontinued
Reference number: GID-TA11074
Following a regulatory update from the company NICE will stop the scope consultation and rearrange the scoping exercise for a later date.
The appraisal is now anticipated to begin late November 2024, with an anticipated evidence submission deadline to NICE of early February 2025, when we will write to you about how to get involved.